Skin cancer and Parkinson's disease
Identifieur interne : 001941 ( Istex/Corpus ); précédent : 001940; suivant : 001942Skin cancer and Parkinson's disease
Auteurs : Joaquim J. Ferreira ; Dulce Neutel ; Tiago Mestre ; Miguel Coelho ; Mário M. Rosa ; Olivier Rascol ; Cristina SampaioSource :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
Abstract
The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22855
Links to Exploration step
ISTEX:E07B15D78830DC683FDBACB04F513F13EB3845E3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Skin cancer and Parkinson's disease</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E07B15D78830DC683FDBACB04F513F13EB3845E3</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22855</idno><idno type="url">https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001941</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001941</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Skin cancer and Parkinson's disease</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30">2010-01-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="139">139</biblScope><biblScope unit="page" to="148">148</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E07B15D78830DC683FDBACB04F513F13EB3845E3</idno><idno type="DOI">10.1002/mds.22855</idno><idno type="ArticleID">MDS22855</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cancer</term><term>melanoma</term><term>skin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Joaquim J. Ferreira MD, PhD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string><json:string>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Dulce Neutel MD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Tiago Mestre MD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Miguel Coelho MD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Mário M. Rosa MD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>melanoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>skin</value></json:item></subject><articleId><json:string>MDS22855</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.52</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1362</abstractCharCount><pdfWordCount>5679</pdfWordCount><pdfCharCount>37741</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>210</abstractWordCount></qualityIndicators><title>Skin cancer and Parkinson's disease</title><refBibs><json:item><author><json:item><name>JL Skibba</name></json:item><json:item><name>J Pinckley</name></json:item><json:item><name>EF Gilbert</name></json:item><json:item><name>RO Johnson</name></json:item></author><host><volume>93</volume><pages><last>561</last><first>556</first></pages><author></author><title>Arch Pathol</title></host><title>Multiple primary melanoma following administration of levodopa</title></json:item><json:item><author><json:item><name>W Pfutzner</name></json:item><json:item><name>B Przybilla</name></json:item></author><host><volume>37</volume><pages><last>336</last><first>332</first></pages><author></author><title>J Am Acad Dermatol</title></host><title>Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature</title></json:item><json:item><host><pages><first>1111</first></pages><author></author><title>Medical Economics Company, Inc.Physicians' desk reference.57th ed.Montvale, NJ:Medical Economics Company, Inc.,2003. p1111.</title></host></json:item><json:item><author><json:item><name>J Kincannon</name></json:item><json:item><name>C Boutzale</name></json:item></author><host><volume>104</volume><pages><last>1045</last><first>1042</first></pages><author></author><title>Pediatrics</title></host><title>The physiology of pigmented nevi</title></json:item><json:item><author><json:item><name>JF Siple</name></json:item><json:item><name>DC Schneider</name></json:item><json:item><name>WA Wanlass</name></json:item><json:item><name>BK Rosenblatt</name></json:item></author><host><volume>34</volume><pages><last>385</last><first>382</first></pages><author></author><title>Ann Pharmacother</title></host><title>Levodopa therapy and the risk of malignant melanoma</title></json:item><json:item><author><json:item><name>KH Fiala</name></json:item><json:item><name>J Whetteckey</name></json:item><json:item><name>BV Manyam</name></json:item></author><host><volume>9</volume><pages><last>327</last><first>321</first></pages><author></author><title>Parkinsonism Relat Disord</title></host><title>Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>62</volume><pages><last>248</last><first>241</first></pages><author></author><title>Arch Neurol</title></host><title>A randomized placebo‐controlled trial of rasagiline in levodopa‐treated patients with Parkinson disease and motor fluctuations: the PRESTO study</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>59</volume><pages><last>1943</last><first>1937</first></pages><author></author><title>Arch Neurol</title></host><title>A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study</title></json:item><json:item><host><author></author><title>Teva Pharmaceutical Industries Ltd.Azilect® package insert. Kfar Saba,Israel:Teva Pharmaceutical Industries Ltd;2006.</title></host></json:item><json:item><host><author></author><title>Boehringer Ingelheim International GmbH.Mirapex® package insert.Ridgefield, CT:Boehringer Ingelheim International GmbH;2006.</title></host></json:item><json:item><host><author></author><title>GlaxoSmithKline.Requip® package insert.Research Triangle Park, NC:GlaxoSmithKline;2005.</title></host></json:item><json:item><host><author></author><title>Valeant Pharmaceuticals International.Zelapar® package insert.Costa Mesa, CA:Valeant Pharmaceuticals International;2006.</title></host></json:item><json:item><author><json:item><name>LJ Doshay</name></json:item></author><host><volume>156</volume><pages><last>684</last><first>680</first></pages><author></author><title>J Am Med Assoc</title></host><title>Problem situations in the treatment of paralysis agitans</title></json:item><json:item><author><json:item><name>KHA Westlund</name></json:item></author><host><volume>162</volume><pages><first>1003</first></pages><author></author><title>JAMA</title></host><title>Cancer as a cause of death among patients with other chronic disease</title></json:item><json:item><author><json:item><name>A JJ‐G Barbeau</name></json:item></author><host><volume>92</volume><pages><last>174</last><first>169</first></pages><author></author><title>L'Union Med du Canada</title></host><title>Parkinson et cancer</title></json:item><json:item><author><json:item><name>MM Hoehn</name></json:item><json:item><name>MD Yahr</name></json:item></author><host><volume>17</volume><pages><last>442</last><first>427</first></pages><author></author><title>Neurology</title></host><title>Parkinsonism: onset, progression and mortality</title></json:item><json:item><author><json:item><name>PB Pritchard III</name></json:item><json:item><name>MG Netsky</name></json:item></author><host><volume>23</volume><pages><last>222</last><first>215</first></pages><author></author><title>Neurology</title></host><title>Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study</title></json:item><json:item><author><json:item><name>H Harada</name></json:item><json:item><name>S Nishikawa</name></json:item><json:item><name>K Takahashi</name></json:item></author><host><pages><first>40</first></pages><author></author><title>Arch Neurol</title></host><title>Epidemiology of Parkinson's disease in a Japanese city</title></json:item><json:item><author><json:item><name>B Jansson</name></json:item><json:item><name>J Jankovic</name></json:item></author><host><volume>17</volume><pages><last>509</last><first>505</first></pages><author></author><title>Ann Neurol</title></host><title>Low cancer rates among patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>AH Rajput</name></json:item><json:item><name>KP Offord</name></json:item><json:item><name>CM Beard</name></json:item><json:item><name>LT Kurland</name></json:item></author><host><volume>37</volume><pages><last>232</last><first>226</first></pages><author></author><title>Neurology</title></host><title>A case—control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease</title></json:item><json:item><author><json:item><name>JM JCRB Gorell</name></json:item></author><host><volume>44</volume><pages><last>1868</last><first>1865</first></pages><author></author><title>Neurology</title></host><title>Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970–1990</title></json:item><json:item><author><json:item><name>H Moller</name></json:item><json:item><name>L Mellemkjaer</name></json:item><json:item><name>JK McLaughlin</name></json:item><json:item><name>JH Olsen</name></json:item></author><host><volume>310</volume><pages><last>1501</last><first>1500</first></pages><author></author><title>BMJ</title></host><title>Occurrence of different cancers in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>YMM Ben‐Shlomo</name></json:item></author><host><volume>58</volume><pages><last>299</last><first>293</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?</title></json:item><json:item><author><json:item><name>R Raschetti</name></json:item><json:item><name>S Spila‐Alegiani</name></json:item><json:item><name>N Vanacore</name></json:item><json:item><name>C Ancona</name></json:item><json:item><name>G Meco</name></json:item></author><host><volume>97</volume><pages><last>26</last><first>20</first></pages><author></author><title>Acta Neurol Scand</title></host><title>Mortality in a population‐based cohort of patients treated with antiparkinsonian drugs</title></json:item><json:item><author><json:item><name>N Vanacore</name></json:item><json:item><name>S Spila‐Alegiani</name></json:item><json:item><name>R Raschetti</name></json:item><json:item><name>G Meco</name></json:item></author><host><volume>52</volume><pages><last>398</last><first>395</first></pages><author></author><title>Neurology</title></host><title>Mortality cancer risk in parkinsonian patients: a population‐based study</title></json:item><json:item><author><json:item><name>Y Minami</name></json:item><json:item><name>R Yamamoto</name></json:item><json:item><name>M Nishikouri</name></json:item><json:item><name>A Fukao</name></json:item><json:item><name>S Hisamichi</name></json:item></author><host><volume>247</volume><pages><last>434</last><first>429</first></pages><author></author><title>J Neurol</title></host><title>Mortality and cancer incidence in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>A Elbaz</name></json:item><json:item><name>BJ Peterson</name></json:item><json:item><name>P Yang</name></json:item></author><host><volume>13</volume><pages><last>164</last><first>157</first></pages><author></author><title>Epidemiology</title></host><title>Nonfatal cancer preceding Parkinson's disease: a case‐control study</title></json:item><json:item><author><json:item><name>A Elbaz</name></json:item><json:item><name>BJ Peterson</name></json:item><json:item><name>JH Bower</name></json:item></author><host><volume>20</volume><pages><last>725</last><first>719</first></pages><author></author><title>Mov Disord</title></host><title>Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study</title></json:item><json:item><author><json:item><name>M D'Amelio</name></json:item><json:item><name>P Ragonese</name></json:item><json:item><name>L Morgante</name></json:item></author><host><volume>19</volume><pages><last>811</last><first>807</first></pages><author></author><title>Mov Disord</title></host><title>Tumor diagnosis preceding Parkinson's disease: a case–control study</title></json:item><json:item><author><json:item><name>JH Olsen</name></json:item><json:item><name>S Friis</name></json:item><json:item><name>K Frederiksen</name></json:item><json:item><name>JK McLaughlin</name></json:item><json:item><name>L Mellemkjaer</name></json:item><json:item><name>H Moller</name></json:item></author><host><volume>92</volume><pages><last>205</last><first>201</first></pages><author></author><title>Br J Cancer</title></host><title>Atypical cancer pattern in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>JA Driver</name></json:item><json:item><name>T Kurth</name></json:item><json:item><name>JE Buring</name></json:item><json:item><name>JM Gaziano</name></json:item><json:item><name>G Logroscino</name></json:item></author><host><volume>18</volume><pages><last>711</last><first>705</first></pages><author></author><title>Cancer Causes Control</title></host><title>Prospective case‐control study of nonfatal cancer preceding the diagnosis of Parkinson's disease</title></json:item><json:item><author><json:item><name>JA Driver</name></json:item><json:item><name>G Logroscino</name></json:item><json:item><name>JE Buring</name></json:item><json:item><name>JM Gaziano</name></json:item><json:item><name>T Kurth</name></json:item></author><host><volume>16</volume><pages><last>1265</last><first>1260</first></pages><author></author><title>Cancer Epidemiol Biomarkers Prev</title></host><title>A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease</title></json:item><json:item><author><json:item><name>JH Olsen</name></json:item><json:item><name>S Friis</name></json:item><json:item><name>K Frederiksen</name></json:item></author><host><volume>17</volume><pages><last>587</last><first>582</first></pages><author></author><title>Epidemiology</title></host><title>Malignant melanoma and other types of cancer preceding Parkinson disease</title></json:item><json:item><author><json:item><name>R Inzelberg</name></json:item><json:item><name>JM Rabey</name></json:item><json:item><name>R Djaldetti</name></json:item></author><host><volume>22</volume><pages><first>169</first></pages><author></author><title>Mov Disord</title></host><title>Elevated prevalence of malignant melanoma in Israeli patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>JM Bertoni</name></json:item><json:item><name>JP Arlette</name></json:item><json:item><name>HH Fernandez</name></json:item></author><host><volume>60</volume><pages><last>72</last><first>71</first></pages><issue>Suppl 3</issue><author></author><title>Ann Neurol</title></host><title>Parkinson's disease and melanoma: an epidemiologic evaluation</title></json:item><json:item><author><json:item><name>J Ferreira</name></json:item><json:item><name>JM Silva</name></json:item><json:item><name>R Freire</name></json:item></author><host><volume>22</volume><pages><last>1475</last><first>1471</first></pages><author></author><title>Mov Disord</title></host><title>Skin cancers and precancerous lesions in Parkinson's disease patients</title></json:item><json:item><author><json:item><name>R Constantinescu</name></json:item><json:item><name>M Romer</name></json:item><json:item><name>K Kieburtz</name></json:item></author><host><volume>22</volume><pages><last>722</last><first>720</first></pages><author></author><title>Mov Disord</title></host><title>Malignant melanoma in early Parkinson's disease: the DATATOP trial</title></json:item><json:item><author><json:item><name>DS Rigel</name></json:item><json:item><name>Z Patel</name></json:item><json:item><name>J Bolognia</name></json:item><json:item><name>C Eichler</name></json:item><json:item><name>DL Ellis</name></json:item><json:item><name>RJ Friedman</name></json:item></author><host><volume>21</volume><pages><first>58.</first></pages><author></author><title>Mov Disord</title></host><title>Evaluation of Parkinson's disease (PD) prevalence in patients with malignant melanoma</title></json:item><json:item><author><json:item><name>PD Baade</name></json:item><json:item><name>L Fritschi</name></json:item><json:item><name>DM Freedman</name></json:item></author><host><volume>28</volume><pages><last>20</last><first>16</first></pages><author></author><title>Neuroepidemiology</title></host><title>Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients</title></json:item><json:item><author><json:item><name>AJ Sober</name></json:item><json:item><name>MM Wick</name></json:item></author><host><volume>240</volume><pages><last>555</last><first>554</first></pages><author></author><title>JAMA</title></host><title>Levodopa therapy and malignant melanoma</title></json:item><json:item><author><json:item><name>MM Wick</name></json:item><json:item><name>L Byers</name></json:item><json:item><name>E Frei III</name></json:item></author><host><volume>197</volume><pages><last>469</last><first>468</first></pages><author></author><title>Science</title></host><title>L‐dopa: selective toxicity for melanoma cells in vitro</title></json:item><json:item><author><json:item><name>H Gurney</name></json:item><json:item><name>A Coates</name></json:item><json:item><name>R Kefford</name></json:item></author><host><volume>96</volume><pages><last>87</last><first>85</first></pages><author></author><title>J Invest Dermatol</title></host><title>The use of L‐dopa and carbidopa in metastatic malignant melanoma</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>62</volume><pages><last>248</last><first>241</first></pages><author></author><title>Arch Neurol</title></host><title>A randomized placebo‐controlled trial of rasagiline in levodopa‐treated patients with Parkinson disease and motor fluctuations: the PRESTO study</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>59</volume><pages><last>1943</last><first>1937</first></pages><author></author><title>Arch Neurol</title></host><title>A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study</title></json:item><json:item><author><json:item><name>AN Lieberman</name></json:item><json:item><name>JL Shupack</name></json:item></author><host><volume>24</volume><pages><last>343</last><first>340</first></pages><author></author><title>Neurology</title></host><title>Levodopa and melanoma</title></json:item><json:item><author><json:item><name>AS Kochar</name></json:item></author><host><volume>79</volume><pages><last>121</last><first>119</first></pages><author></author><title>Am J Med</title></host><title>Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature</title></json:item><json:item><author><json:item><name>WJ Weiner</name></json:item><json:item><name>C Singer</name></json:item><json:item><name>JR Sanchez‐Ramos</name></json:item><json:item><name>JN Goldenberg</name></json:item></author><host><volume>43</volume><pages><last>677</last><first>674</first></pages><author></author><title>Neurology</title></host><title>Levodopa, melanoma, and Parkinson's disease</title></json:item><json:item><author><json:item><name>DC Whiteman</name></json:item><json:item><name>M Stickley</name></json:item><json:item><name>P Watt</name></json:item><json:item><name>MC Hughes</name></json:item><json:item><name>MB Davis</name></json:item><json:item><name>AC Green</name></json:item></author><host><volume>24</volume><pages><last>3177</last><first>3172</first></pages><author></author><title>J Clin Oncol</title></host><title>Anatomic site, sun exposure, and risk of cutaneous melanoma</title></json:item><json:item><author><json:item><name>GB Ivry</name></json:item><json:item><name>CA Ogle</name></json:item><json:item><name>EK Shim</name></json:item></author><host><volume>32</volume><pages><last>492</last><first>481</first></pages><author></author><title>Dermatol Surg</title></host><title>Role of sun exposure in melanoma</title></json:item><json:item><author><json:item><name>WJ Weiner</name></json:item><json:item><name>C Singer</name></json:item><json:item><name>JR Sanchez‐Ramos</name></json:item><json:item><name>JN Goldenberg</name></json:item></author><host><volume>43</volume><pages><last>677</last><first>674</first></pages><author></author><title>Neurology</title></host><title>Levodopa, melanoma, and Parkinson's disease</title></json:item><json:item><author><json:item><name>R Sandyk</name></json:item></author><host><volume>63</volume><pages><last>140</last><first>137</first></pages><author></author><title>Int J Neurosci</title></host><title>Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland</title></json:item><json:item><author><json:item><name>AE Boyd III</name></json:item><json:item><name>HE Lebovitz</name></json:item><json:item><name>JB Pfeiffer</name></json:item></author><host><volume>283</volume><pages><last>1429</last><first>1425</first></pages><author></author><title>N Engl J Med</title></host><title>Stimulation of human‐growth‐hormone secretion by L‐dopa</title></json:item><json:item><author><json:item><name>FH Rampen</name></json:item></author><host><volume>48</volume><pages><last>588</last><first>585</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Levodopa and melanoma: three cases and review of literature</title></json:item><json:item><author><json:item><name>DS Rigel</name></json:item><json:item><name>JA Carucci</name></json:item></author><host><volume>50</volume><pages><last>236</last><first>215</first></pages><author></author><title>CA Cancer J Clin</title></host><title>Malignant melanoma: prevention, early detection, and treatment in the 21st century</title></json:item></refBibs><genre><json:string>review-article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>10</total><last>148</last><first>139</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22855</json:string></doi><id>E07B15D78830DC683FDBACB04F513F13EB3845E3</id><score>0.14826731</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Skin cancer and Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2009 Movement Disorder Society</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Skin cancer and Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Joaquim J.</forename><surname>Ferreira</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><affiliation>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</affiliation></author><author xml:id="author-2"><persName><forename type="first">Dulce</forename><surname>Neutel</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-3"><persName><forename type="first">Tiago</forename><surname>Mestre</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-4"><persName><forename type="first">Miguel</forename><surname>Coelho</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-5"><persName><forename type="first">Mário M.</forename><surname>Rosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-6"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="139">139</biblScope><biblScope unit="page" to="148">148</biblScope></imprint></monogr><idno type="istex">E07B15D78830DC683FDBACB04F513F13EB3845E3</idno><idno type="DOI">10.1002/mds.22855</idno><idno type="ArticleID">MDS22855</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>cancer</term></item><item><term>melanoma</term></item><item><term>skin</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-04-07">Received</change><change when="2009-09-29">Registration</change><change when="2010-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v25:2</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2010-01-30">30 January 2010</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22855</doi><idGroup><id type="unit" value="MDS22855"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-04-07"></event><event type="manuscriptRevised" date="2009-09-28"></event><event type="manuscriptAccepted" date="2009-09-29"></event><event type="firstOnline" date="2010-01-08"></event><event type="publishedOnlineFinalForm" date="2010-02-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-01-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">139</numbering><numbering type="pageLast">148</numbering></numberingGroup><correspondenceTo>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22855.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="54"></count><count type="wordTotal" number="7249"></count></countGroup><titleGroup><title type="main" xml:lang="en">Skin cancer and Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Skin Cancer and Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Joaquim J.</givenNames><familyName>Ferreira</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>joaquimjferreira@net.sapo.pt</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Dulce</givenNames><familyName>Neutel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Tiago</givenNames><familyName>Mestre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Miguel</givenNames><familyName>Coelho</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mário M.</givenNames><familyName>Rosa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="PT" type="organization"><unparsedAffiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">cancer</keyword><keyword xml:id="kwd3">melanoma</keyword><keyword xml:id="kwd4">skin</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Skin cancer and Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Skin Cancer and Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Skin cancer and Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Joaquim J.</namePart><namePart type="family">Ferreira</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><affiliation>Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649‐028 Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dulce</namePart><namePart type="family">Neutel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tiago</namePart><namePart type="family">Mestre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Miguel</namePart><namePart type="family">Coelho</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mário M.</namePart><namePart type="family">Rosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-01-30</dateIssued><dateCaptured encoding="w3cdtf">2008-04-07</dateCaptured><dateValid encoding="w3cdtf">2009-09-29</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">54</extent><extent unit="words">7249</extent></physicalDescription><abstract lang="en">The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>cancer</topic><topic>melanoma</topic><topic>skin</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>139</start><end>148</end><total>10</total></extent></part></relatedItem><identifier type="istex">E07B15D78830DC683FDBACB04F513F13EB3845E3</identifier><identifier type="DOI">10.1002/mds.22855</identifier><identifier type="ArticleID">MDS22855</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001941 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001941 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E07B15D78830DC683FDBACB04F513F13EB3845E3
|texte= Skin cancer and Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |